Wereport a 65-year-old womanwith thyrotropin (TSH) secreting pituitary adenoma, who was diagnosed based on the lack of inhibition of serum TSHdespite an increased serum free thyroxine (T4), a low response of serum TSHto thyrotropin releasing hormone, and a pituitary tumor as revealed by magnetic resonance imaging. The pituitary adenoma was, however, inoperable due to chronic respiratory failure. The treatment with octreotide in a dose of 100 |ig b.i.d. resulted in inhibition of serum TSHand free T4 to euthyroid levels and considerable shrinkage of the pituitary tumor. These effects were continued over 8 months after the start ofoctreotide therapy without any adverse effects. These findings add further evidence that octreotide is useful for treating inoperable TSH secreting pituitary adenoma.
Introduction
Thyrotropin (thyroid stimulating hormone; TSH) secreting pituitary adenomas primarily present clinical symptomsand signs of hyperthyroidism, indistinguishable from those caused by primary hyperthyroidism. Normal or elevated serum TSHis associated with increased serum thyroid hormone levels. The frequency of TSHsecreting pituitary adenomas is 0.2-2.0% among all the pituitary tumors (1-6).
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The principal treatment for TSH secreting adenoma is transsphenoidal surgery. However,the surgical outcome is not satisfactory in patients with suprasellar expansion of the pituitary tumor. In fact, most TSHsecreting pituitary tumors are macroadenoma with suprasellar extension or cavernoussinus invasion whenadenomas are detected. The surgically curable rate is reported to be only 26% (27/1 02) (7) . Recently, octreotide, a long-acting somatostatin analog, has been reported to be effective for TSH secreting pituitary adenoma (8, 9) .
In this report, we present a case of TSHsecreting pituitary adenomawithout operative indication due to chronic respiratory failure, and the effects of octreotide on the tumor shrinkage and the reduction of serum hormonelevels.
Case Report
A 65-year-old womanwas referred to our hospital for further examination of weight loss. She had suffered from pulmonary tuberculosis with pleuritis at the age of 15 years, and the left upper lobe was resected at the age of 26 years. There were no thyroid diseases in her family and past history. Body weight was 38 kg at the age of 59 years and gradually decreased thereafter. She suffered from chronic respiratory failure due to old pulmonary tuberculosis at the age of 63 years and at times she had prolonged severe respiratory symptomof upper respiratory infection.
On admission, she was 150 cm tall and weighed 26 kg (body mass index; 1 1.6 kg/m2) despite sufficient food intake. Heart rate was 100/min, blood pressure was 130/86 mmHg, body temperature was 36.8-37.5°C, and respiratory rate showed tachypnea of 30/min. The skin moisture was normal. There were no exophthalmos, hand tremor or goiter. Her breath sound was decreased in the left upper lung field. Oral glucose tolerance test revealed impaired glucose tolerFrom the First Department of Internal Medicine, Nagasaki University School of Medicine and *the Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki Received for publication January 26, 1998; Accepted for publication August 10, 1998 Reprint requests should be addressed to Dr. Katsumi Eguchi, the First Department of Internal Medicine, Nagasaki University School of Medicine, 1 -7-1 , Sakamoto, Nagasaki 852-8501
Internal Medicine Vol. 37, No. 12 (December 1998) Table 1 shows the endocrinological data. Serum free thyroxine (free T4) was 2.21 ng/dl, free 3,5,3'-triiodothyronine (free T3) was 4.0 pg/ml, and TSH was 3.18 [iU/ml. Serum thyroglobulin level was high and all thyroidal autoantibodies were negative. Radioactive iodine (123I) uptake were 20.5% (4 hours) and 34.8% (24 hours), respectively.
Pituitary function test TSHSecreting AdenomaTreated with Octreotide showedthe reduced serum TSHresponse to thyrotropin-releasing hormone (TRH) (Fig. 1 ). Radiological study with magnetic resonance imaging (MRI) revealed a delay-enhanced pituitary tumor with suprasellar extension measuring 10 mmin diameter and the pituitary stalk was shifted to the left ( Fig. 2A) . Hypothalamic hypogonadism on luteinizing hormone-releasing hormone (LH-RH) tolerance test and increased levels of plasma adrenocorticotropic hormone (ACTH)and serum cortisol were also detected.
Octreotide (Sandostatin®) was administrated subcutaneously 100 jag twice a day. The nature of the treatment was fully explained and informed consent was obtained before the start of treatment. Serum TSHand free T4 levels started to decrease within a week and she was in the euthyroid state after a few weeks of the treatment (Fig. 3) . The change in the serum free T3 level was also associated with that of free T4. Pituitary MRI showed a considerable tumor shrinkage over eight months after the start of the treatment (Fig. 2B, C) . Glucose intolerance was ameliorated to a normal glucose level. Her body temperature and heart rate were clinically stabilized at 36.5-36.8°C and 70/ min, respectively. The reduction of body weight was suspended and furthermore her body weight mildly increased to 29 kg. These effects were continued over 8 monthsafter the start of octreotide therapy. Octreotide is thought to ameliorate endocrine functions and reduce tumor size. It is reported that serum levels of TSHand thyroid hormones returned to normal in 73% of patients, and tumor shrinkage was observed in 40%of patients managedwith long-term octreotide therapy (8, 9) . Octreotide is generally administrated subcutaneously two or three times per day (200-300 jig/day) in order to produce an effective inhibition of TSH secretion. In the present case, octreotide (200 jig/day) inhibited TSHsecretion and reduced the tumor size at morethan 8 months after the start of treatment. Long-term treatment with octreotide may be associated with the increased likelihood of development of adverse effects, notably gall stone formation (2 1 ). After 8 monthsof therapy, no adverse effect and the escape phenomenon have been observed in the present case.
Weconclude that octreotide therapy is a suitable means of managementfor the amelioration of thyroid function and reduction of tumor size in inoperable patients with TSH-secreting pituitary adenoma. In addition, considering the effect of tumor shrinkage for improvement of the surgical remission rate, octreotide therapy could be indicated in patients with suprasellar extension ofTSH-secreting pituitary adenomabefore undergoing surgical treatment. Figure3. Sequential changes in serum TSH and free T4 levels after octreotide therapy. Octreotide was injected sc in a dose of lOO jig b.Ld.
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